Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review

Pirfenidone and nintedanib are antifibrotic medications approved for idiopathic pulmonary fibrosis treatment by regulatory agencies and available for clinical use worldwide. These drugs have been shown to reduce the rate of decline in forced vital capacity and the risk of acute exacerbation among pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Amati, Francesco, Stainer, Anna, Polelli, Veronica, Mantero, Marco, Gramegna, Andrea, Blasi, Francesco, Aliberti, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178294/
https://www.ncbi.nlm.nih.gov/pubmed/37175556
http://dx.doi.org/10.3390/ijms24097849

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178294/
https://www.ncbi.nlm.nih.gov/pubmed/37175556
http://dx.doi.org/10.3390/ijms24097849

Ejemplares similares